Annovis Bio, Inc. — Form 8-K
Filed July 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Annovis Bio announced full enrollment of 850 patients (exceeding original projections) in its pivotal Phase 3 trial of buntanetap for early Alzheimer's disease across 83 US clinical sites. The trial has two pre-specified readouts: 6-month symptomatic data in Q1 2027 and 18-month disease-modifying data in Q1 2028, each intended to support separate NDA submissions to the FDA. This milestone positions the company to advance toward regulatory submissions for what could be its first marketed drug.
Why this rating
Enrollment of 850 (vs. original goal) de-risks pivotal trial for $36M company; Phase 3 success could transform from clinical-stage to revenue-generating. Material near-term catalyst (data readouts 2027-28).
See more from July 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.